Sarcoma Residuals Documentation
Soft tissue sarcoma treatment — limb-sparing surgery, radiation, and chemotherapy — leaves lasting functional deficits. REE Medical specialists document these residuals with the clinical specificity VA rating officers require for maximum combined ratings.
Explore REE Medical's Sarcoma Residuals Services →claim.vet may receive a referral fee if you use this link. Veterans never pay more.
Under 38 CFR § 3.309(e), VA recognizes certain diseases as presumptively associated with herbicide exposure. Soft tissue sarcoma occupies a uniquely prominent position on this list — not as a single condition but as an entire category of related cancers, reflecting the scientific evidence that dioxin exposure is specifically linked to sarcoma development.
The scientific basis for this presumptive rests in part on studies of industrial workers and agricultural populations exposed to chlorophenoxy herbicides (the class of compounds that includes 2,4-D and 2,4,5-T, the components of Agent Orange). These studies documented elevated rates of soft tissue sarcoma in exposed populations, providing the epidemiological foundation for the VA's regulatory presumptive.
The legal mechanics work in two steps. First, under 38 CFR § 3.307(a)(6), veterans who served in the Republic of Vietnam between January 9, 1962 and May 7, 1975 are legally presumed to have been exposed to herbicide agents — no individual proof of Agent Orange contact is required. Second, under 38 CFR § 3.309(e), any of the listed soft tissue sarcoma subtypes developing in such veterans is presumptively service-connected. Together, these regulations mean that a Vietnam veteran with a qualifying sarcoma diagnosis can claim service connection without a nexus letter.
Vietnam veterans with qualifying service dates and a diagnosis of any covered soft tissue sarcoma subtype need only file VA Form 21-526EZ with: (1) their DD-214 confirming Vietnam service, and (2) their pathology report confirming the sarcoma diagnosis. VA cannot require a nexus letter when the presumptive applies. If VA demands one anyway, cite 38 CFR § 3.309(e) and file a Notice of Disagreement if denied improperly.
This is a critical section — many veterans don't realize how broad the sarcoma presumptive list is. If your sarcoma diagnosis uses any of the following terms (or is described as a variant, synonym, or subtype of these), it is covered:
| Sarcoma Subtype | Common Clinical Names / Notes |
|---|---|
| Adult fibrosarcoma | Arising in soft tissue of adults (distinct from infantile fibrosarcoma) |
| Dermatofibrosarcoma protuberans (DFSP) | Skin-based low-grade sarcoma; may be locally aggressive |
| Malignant fibrous histiocytoma (MFH) | Now called undifferentiated pleomorphic sarcoma (UPS) in modern pathology terminology |
| Liposarcoma | Arising from fat cells; includes well-differentiated, dedifferentiated, myxoid, and pleomorphic subtypes |
| Leiomyosarcoma | Arising from smooth muscle; common in retroperitoneum, uterus, great vessels |
| Epithelioid leiomyosarcoma (malignant leiomyoblastoma) | Epithelioid variant of leiomyosarcoma |
| Rhabdomyosarcoma | Arising from skeletal muscle; includes embryonal, alveolar, and pleomorphic subtypes |
| Ectomesenchymoma | Rare mixed tumor with both mesenchymal and neural crest features |
| Angiosarcoma (hemangiosarcoma or lymphangiosarcoma) | Arising from blood vessel or lymphatic endothelium |
| Proliferating (systemic) angioendotheliomatosis | Malignant intravascular lymphoma of endothelial derivation |
| Malignant glomus tumor | Malignant variant of benign glomus tumor |
| Malignant hemangiopericytoma | Now classified as solitary fibrous tumor (SFT) in modern terminology |
| Synovial sarcoma (malignant synovioma) | Common in extremities near joints; biphasic or monophasic histology |
| Malignant giant cell tumor of tendon sheath | Malignant variant of GCTTS/pigmented villonodular synovitis |
| Malignant schwannoma (neurofibrosarcoma / neurogenic sarcoma / malignant MPNST) | Malignant peripheral nerve sheath tumor; now called MPNST |
| Malignant mesenchymoma | Mixed sarcoma with two or more differentiated components |
| Malignant granular cell tumor | Malignant variant of granular cell tumor |
| Alveolar soft part sarcoma | Rare; commonly affects young adults; slow-growing but metastatic |
| Epithelioid sarcoma | Often presents in distal extremities; can mimic benign granuloma |
| Clear cell sarcoma of tendons and aponeuroses | Often called "melanoma of soft parts" due to melanin production |
| Extraskeletal Ewing's sarcoma | Ewing's sarcoma NOT arising in bone (soft tissue Ewing's) |
| Congenital and infantile fibrosarcoma | Fibrosarcoma arising in infants/congenitally (rare in veterans context) |
| Malignant ganglioneuroma | Malignant transformation of a ganglioneuroma |
Pathology terminology has evolved since the original regulatory language was written. If your diagnosis uses a modern equivalent name — such as "undifferentiated pleomorphic sarcoma" (which corresponds to old "malignant fibrous histiocytoma"), "malignant peripheral nerve sheath tumor" (MPNST, corresponding to malignant schwannoma), or "solitary fibrous tumor, malignant" (corresponding to malignant hemangiopericytoma) — the presumptive still applies. If VA disputes the terminology match, request that a knowledgeable VSO or attorney assist in identifying the regulatory equivalent.
The herbicide presumptive applies to veterans who served in the following locations during the listed periods:
| Location | Qualifying Period |
|---|---|
| Republic of Vietnam (in-country) | January 9, 1962 – May 7, 1975 |
| Korean Demilitarized Zone (DMZ) | April 1, 1968 – August 31, 1971 |
| Certain Thailand military bases (perimeter spraying) | 1961–1975 |
| Blue Water Navy — territorial seas of Vietnam | January 9, 1962 – May 7, 1975 (PACT Act 2022) |
| Documented herbicide testing/storage locations | Various |
For veterans who do not qualify for the herbicide presumptive but who have a soft tissue sarcoma diagnosis, the PACT Act burn pit presumptive may apply if they served in qualifying Gulf War era or post-9/11 locations. See our PACT Act presumptive conditions guide for details. Additionally, direct service connection for sarcoma may be available for veterans with documented occupational chemical exposure (solvents, herbicides, industrial chemicals) during service, even without the presumptive.
VA rates soft tissue sarcoma under the malignant neoplasm Diagnostic Code appropriate to the anatomical location of the tumor. The most commonly applicable codes include:
| DC | Location | Active Treatment Rating |
|---|---|---|
| 5329 | Malignant neoplasm of muscle and soft tissue (extremity) | 100% during treatment |
| 7343 | Malignant neoplasm of retroperitoneum and peritoneum | 100% during treatment |
| 7528 | Malignant neoplasms of genitourinary system | 100% during treatment |
| 7101+ | Systemic sarcoma (based on organ system involved) | 100% during treatment |
| 7833 | Dermatofibrosarcoma protuberans (skin-based sarcoma) | 100% during treatment |
Regardless of the specific DC, the 100% rating during active treatment is a universal principle for malignant neoplasms under 38 CFR § 4.117. The rating begins as of the date of histologic diagnosis (retroactive to diagnosis if claimed within one year) and continues throughout all active treatment phases.
Six months after the cessation of all active treatment (including adjuvant chemotherapy or radiation), VA re-evaluates under the applicable residuals DCs. For soft tissue sarcoma — particularly sarcomas treated with surgery and radiation — the residuals can be significant:
Wide local excision for extremity sarcomas leaves significant surgical wounds that often require reconstructive procedures. The resulting scars are rated under DC 7800-7805. More importantly, damage to muscles, tendons, and nerves during excision can cause lasting range of motion limitations, weakness, and functional impairment in the affected limb:
Radiation therapy for extremity sarcoma is a primary cause of radiation fibrosis — stiffening and scarring of irradiated tissue — and lymphedema if lymphatic drainage is disrupted. Lymphedema of an extremity is rated based on severity:
| Lymphedema Severity | Approximate VA Rating |
|---|---|
| Mild (slight swelling, minimal functional impact) | 10% |
| Moderate (moderate swelling, impairs some activities) | 20-30% |
| Severe (massive swelling, skin changes, significant functional loss) | 40-60% |
Ifosfamide and vincristine — used in some sarcoma regimens — are neurotoxic and can cause lasting peripheral neuropathy. Doxorubicin also has neurotoxic potential. Chemotherapy-induced peripheral neuropathy (CIPN) is rated under the peripheral nerve codes (DC 8510-8620) based on the nerves affected and severity. As with other chemotherapy-related neuropathies, the standard rating criteria apply: mild (10%), moderate (20%), moderately severe (40%), severe with muscle atrophy (60%).
Doxorubicin (adriamycin) is the cornerstone of many sarcoma chemotherapy regimens. It is also a known cardiotoxin. Veterans who received significant cumulative doses of doxorubicin should have cardiac evaluation — specifically echocardiogram to assess left ventricular ejection fraction (LVEF) — as part of their residuals claim. Cardiomyopathy and decreased ejection fraction are ratable under DC 7000-7020 at rates from 10% (asymptomatic) to 100% (severe CHF).
For sarcomas where limb-sparing surgery was not feasible, amputation may be the treatment of choice. VA rates amputations under DC 5150-5170 (arm) and DC 5160-5170 (leg), with specific ratings based on the level of amputation:
| Amputation Level | Rating (Dominant Side) | Rating (Non-Dominant) |
|---|---|---|
| Above elbow (AE) | 80% | 70% |
| Below elbow (BE) | 60% | 50% |
| Above knee (AK) / Thigh | 90% | 80% |
| Below knee (BK) | 60% | 60% |
| Amputation preventing prosthetic use | Higher rates apply |
Veterans with amputations secondary to sarcoma also qualify for Automobile and Adaptive Equipment Allowances (38 U.S.C. § 3902) and may qualify for Specially Adapted Housing (SAH) grants under 38 U.S.C. § 2101 if the amputation significantly limits mobility within the home.
The most important preliminary step is confirming that your specific sarcoma diagnosis matches one of the named subtypes in 38 CFR § 3.309(e). Obtain your pathology report and compare the diagnosis against the covered list above. If the terminology has changed (e.g., your old report says "malignant fibrous histiocytoma" but modern pathology would call it "undifferentiated pleomorphic sarcoma"), note that these are equivalent for presumptive purposes and reference the regulatory language in your claim.
Whether you're filing for the first time or for a recurrence of previously treated sarcoma, file immediately. The 100% rating is retroactive to the date of diagnosis (or recurrence) only if filed within one year. For a condition rated at 100%, the difference between a timely and delayed claim can represent many months of maximum-rate compensation.
For additional context on Agent Orange presumptives, see our comprehensive guide on Agent Orange presumptive conditions. For veterans whose sarcoma may also be covered by the PACT Act, see our guide on PACT Act presumptive conditions.
Post-Treatment Residuals: Don't Leave Money on the Table
Range of motion deficits, lymphedema, chemotherapy neuropathy, cardiac effects — these all add to your combined rating after sarcoma treatment. REE Medical provides detailed residuals documentation for the six-month re-evaluation that follows your 100% active treatment rating.
Learn About REE Medical's Residuals Services →claim.vet may receive a referral fee if you use this link. Veterans never pay more.
Editorial Standards: Written by Marcus J. Webb, veterans benefits researcher. Verified against current 38 CFR regulations. Last reviewed: July 2026. Not legal advice — for representation, connect with a VA-accredited attorney.
Vietnam service + sarcoma diagnosis = presumptive service connection. Find out what you're owed — free review, no phone calls required.
Start My Free Claim Review — No Phone Required →